



Medications for Neuropathic Pain

B.C. Provincial Academic Detailing Service

November 2018

REFERENCES

Medications for Neuropathic Pain, Evidence for Practice

1. Mu A, Weinberg E, Moulin D, et al. Pharmacologic management of chronic neuropathic pain. Review of the Canadian Pain Society consensus statement. *Can Fam Physician* 2017;63:844-52
2. Finnerup N, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015; 14:162-73
3. National Institute for Health and Care Excellence. Neuropathic pain in adults: pharmacological management in non-specialist settings. [Internet]. <https://www.nice.org.uk/guidance/cg173>
4. Wiffen P, Derry S, Moore R, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia – an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews* 2013, Issue 11. Art. No. CD010567
5. Wiffen P, Derry S, Bell R, et al. Gabapentin for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2017, Issue 6. Art. No. CD007938
6. Moore R, Straube S, Wiffen P, et al. Pregabalin for acute and chronic pain in adults. *Cochrane Database of Systematic Reviews* 2009, Issue 3. Art. No. CD007076
7. Lunn M, Hughes R, Wiffen P. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database of Systematic Reviews* 2014, Issue 1. Art. No. CD007115
8. Canadian Agency for Drugs in Technology and Health. Gabapentin for adults with neuropathic pain: a review of the clinical effectiveness. March 12, 2018. [Internet]. <https://www.cadth.ca/gabapentin-adults-neuropathic-pain-review-clinical-effectiveness-0>
9. Moore R, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No. CD008242
10. Hearne L, Moore R, Derry S, et al. Desipramine for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 9. Art. No. CD011003
11. Hearn L, Derry S, Phillips T, et al. Imipramine for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 5. Art. No. CD010769
12. Derry S, Wiffen P, Aldington D, et al. Nortriptyline for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2015, Issue 1. Art. No. CD011209
13. US Food and Drug Administration. Neurontin (gabapentin). Postherpetic Neuralgia. 2001. Drug Approval Package. NDA 021397, 021423, 021424. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-397_21-423_21-424_Neurontin.cfm
14. US Food and Drug Administration. Neurontin (gabapentin). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
15. Health Canada. The Drug and Health Product Register. Summary Basis of Decision for LYRICA. 2007. [Internet]. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne.php?linkID=SBD00089>
16. Health Canada Product Monograph. Lyrica (pregabalin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
17. US Food and Drug Administration. Lyrica (pregabalin). Drug Approval Package. Diabetic Peripheral Neuropathy. 2004. NDA 021446 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_LyricaTOC.cfm
18. US Food and Drug Administration. Lyrica (pregabalin). Drug Approval Package. Postherpetic Neuralgia. 2004. NDA 021723 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021723s000_LyricaCapsTOC.cfm
19. US Food and Drug Administration. Lyrica (pregabalin). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021446s026,022488s005lbl.pdf

20. Health Canada. The Drugs and Health Product Register. Summary Basis of Decision for CYMBALTA. 2008. [Internet]. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne.php?linkID=SBD00040>
21. Health Canada Product Monograph. Cymbalta (duloxetine delayed release capsules). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
22. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride). Drug Approval Package. Diabetic Peripheral Neuropathy. NDA 021733 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021733s000_CymbaltaTOC.cfm
23. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride delayed release capsules). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516lbl.pdf
24. Therapeutics Letter 96. Benefits and harms of drugs for “neuropathic” pain. September – October 2015. [Internet]. <https://www.ti.ubc.ca/2016/01/19/96-benefits-and-harms-of-drugs-for-neuropathic-pain/>
25. Chapparro L, Wiffen P, Moore R, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No. CD008943
26. Gomes T, Juurlink D, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med 2017;14:e1002396
27. Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med 2018 Aug 21 [Epub ahead of print].

Evidence Brief using the Cochrane Library

1. Wiffen P, Derry S, Bell R, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No. CD0007938
2. Moore R, Straube S, Wiffen P, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No. CD007076
3. Wiffen P, Derry S, Moore R, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No. CD005451
4. Hearn L, Derry S, Moore R. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No. CD009318
5. Wiffen P, Derry S, Moore R. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No. CD006044
6. Lunn M, Hughes R, Wiffen P. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No. CD007115
7. Gallagher H, Gallagher R, Butler M, et al. Venlafaxine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 8. Art. No. CD011091
8. Moore R, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No. CD008242
9. Hearne L, Moore R, Derry S, et al. Desipramine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 9. Art. No. CD011003
10. Derry S, Wiffen P, Aldington D, et al. Nortriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No. CD011209
11. Wiffen P, Derry S, Moore R, et al. Levetiracetam for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No. CD012499
12. Zhou M, Chen N, He L, et al. Oxcarbazepine for neuropathic pain. Cochrane Database of Systematic Reviews 2017, Issue 12. Art. No. CD007963
13. Wiffen P, Derry S, Lunn M, et al. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No. CD008314
14. Gill D, Derry S, Wiffen P, et al. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No. CD009183
15. Hearn L, Derry S, Phillips T, et al. Imipramine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No. CD010769
16. Stannard C, Gaskell H, Derry S, et al. Hydromorphone for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No. CD011604
17. Cooper T, Chen J, Wiffen P, et al. Morphine for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No. CD011669

18. Gaskell H, Derry S, Stannard C, et al. Oxycodone for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No. CD010692
19. Duehmke R, Derry S, Wiffen P, et al. Tramadol for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No. CD003726
20. Derry S, Stannard C, Cole P, et al. Fentanyl for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No. CD011605
21. McNicol E, Ferguson M, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No. CD010943
22. Mucke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No. CD012182
23. Wiffen P, Knaggs R, Derry S, et al. Paracetamol (acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No. CD012227
24. Moore R, Chi C, Wiffen P, et al. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No. CD010902
25. Chapparro L, Wiffen P, Moore R, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No. CD008943
26. Health Canada Product Monograph. Tegretol (carbamazepine). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>

Gabapentin

1. US Food and Drug Administration. Neurontin (gabapentin). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
2. Health Canada Product Monograph. Neurontin (gabapentin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
3. Therapeutics Letter 75. Gabapentin for pain: New evidence from hidden data. 2009 December 31. [Internet]. <https://www.ti.ubc.ca/2009/12/31/gabapentin-for-pain-new-evidence-from-hidden-data/>
4. Mu A, Weinberg E, Moulin D, et al. Pharmacologic management of chronic neuropathic pain. *Can Fam Physician* 2017;63:844-52
5. Australian Government. Therapeutic Brief 35. Managing neuropathic pain: a stepwise approach. [Internet]. https://www.apsoc.org.au/PDF/Publications/Veterans_MATES_35_Neuropathic_Pain_TherBrief_JUN13.pdf
6. US Food and Drug Administration. Neurontin (gabapentin). Postherpetic Neuralgia. 2001. Drug Approval Package. NDA 021397, 021423, 021424. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-397_21-423_21-424_Neurontin.cfm
7. Wiffen P, Derry S, Bell R, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No. CD007938
8. Health Canada. Summary Safety Review. Gabapentin. Assessing the potential risk of serious breathing problems. 2016 September 16. [Internet]. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-assessing-potential-risk-serious-breathing.html>
9. Throckmorton D, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse – proactive pharmacovigilance. *N Engl J Med* 2018 May 30. [Epub ahead of print].
10. Johansen M. Gabapentinoid use in the United States 2002 through 2015. *JAMA Int Med* 2018;178:292-294
11. Goodman C, Brett A. Gabapentin and pregabalin for pain – is increased prescribing a cause for concern? *N Engl J Med* 2017;377:411-414
12. Government Advisory Council on the Misuse of Drugs. Re: Pregabalin and Gabapentin advice. 14 January 2016. [Internet]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/491854/ACMD_Advice_-_Pregabalin_and_gabapentin.pdf

13. Public Health England and NHS England. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. 11 December 2014. [Internet]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/385791/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf
14. Canadian Agency for Drugs in Technology and Health. Abuse and misuse of gabapentin: clinical evidence, safety, and guidelines. October 19, 2017. [Internet]. <https://www.cadth.ca/abuse-and-misuse-gabapentin-clinical-evidence-safety-and-guidelines-0>
15. Canadian Agency for Drugs in Technology and Health. Gabapentin for adults with neuropathic pain: a review of the clinical effectiveness. March 12, 2018. [Internet]. <https://www.cadth.ca/gabapentin-adults-neuropathic-pain-review-clinical-effectiveness-0>
16. Enke O, New H, New C, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. *CMAJ* 2018;190:E786-E793

Pregabalin

1. Health Canada Product Monograph. Lyrica (pregabalin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
2. Mu A, Weinberg E, Moulin D, et al. Pharmacologic management of chronic neuropathic pain. *Can Fam Physician* 2017;63:844-52
3. Australian Government. Therapeutic Brief 35. Managing neuropathic pain: a stepwise approach. [Internet]. https://www.apsoc.org.au/PDF/Publications/Veterans_MATES_35_Neuropathic_Pain_TherBrief_JUN13.pdf
4. US Food and Drug Administration. Lyrica (pregabalin). Drug Approval Package. Diabetic Peripheral Neuropathy. 2004. NDA 021446 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021446_LyricaTOC.cfm
5. US Food and Drug Administration. Lyrica (pregabalin). Drug Approval Package. Postherpetic Neuralgia. 2004. NDA 021723 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021723s000_LyricaCapsTOC.cfm
6. Health Canada. The Drug and Health Product Register. Summary Basis of Decision for LYRICA. 2007. [Internet]. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne.php?linkID=SBD00089>
7. US Food and Drug Administration. Lyrica (pregabalin). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021446s026,022488s005lbl.pdf
8. Page R, O'Bryant C, Cheng D, et al. Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association. *Circulation* 2016;134:1-38
9. Ho J, Macdonald E, Luo J, et al. Pregabalin and heart failure: a population-based study. *Pharmacoepidemiol Drug Saf* 2017;26:1087-1092
10. Throckmorton D, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse – proactive pharmacovigilance. *N Engl J Med* 2018 May 30. [Epub ahead of print].
11. Johansen M. Gabapentinoid use in the United States 2002 through 2015. *JAMA Int Med* 2018;178:292-294
12. Goodman C, Brett A. Gabapentin and pregabalin for pain – is increased prescribing a cause for concern? *N Engl J Med* 2017;377:411-414
13. Government Advisory Council on the Misuse of Drugs. Re: Pregabalin and Gabapentin advice. 14 January 2016. [Internet]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/491854/ACMD_Advice_-_Pregabalin_and_gabapentin.pdf
14. Public Health England and NHS England. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. 11 December 2014. [Internet]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/385791/PHE-NHS_England_pregabalin_and_gabapentin_advice_Dec_2014.pdf
15. World Health Organization. Expert Committee on Drug Dependence. Pregabalin. Pre-Review Report. Agenda Item 5.1. 6-10 November 2017. [Internet]. <http://www.who.int/medicines/access/controlled-substances/PreReviewPregabalin.pdf>

16. US Drug Enforcement Administration. Diversion Control Division. Docket No. DEA-267F. Schedules of Controlled Substances: Placement of Pregabalin into Schedule V. [Internet]. https://www.deadiversion.usdoj.gov/fed_regs/rules/2005/fr0728.htm
17. Enke O, New H, New C, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. *CMAJ* 2018;190:E786-E793
18. Moore R, Straube S, Wiffen P, et al. Pregabalin for acute and chronic pain in adults. *Cochrane Database of Systematic Reviews* 2009, Issue 3. Art. No. CD007076

Duloxetine

1. Health Canada Product Monograph. Cymbalta (duloxetine delayed release capsules). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
2. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride delayed release capsules). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516lbl.pdf
3. Mu A, Weinberg E, Moulin D, et al. Pharmacologic management of chronic neuropathic pain. *Can Fam Physician* 2017;63:844-52
4. Australian Government. Therapeutic Brief 35. Managing neuropathic pain: a stepwise approach. [Internet]. https://www.apsoc.org.au/PDF/Publications/Veterans_MATES_35_Neuropathic_Pain_TherBrief_JUN13.pdf
5. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride). Drug Approval Package. Diabetic Peripheral Neuropathy. NDA 021733 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021733s000_CymbaltaTOC.cfm
6. Health Canada. The Drugs and Health Product Register. Summary Basis of Decision for CYMBALTA. 2008. [Internet]. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailOne.php?linkID=SBD00040>
7. Maund E, Gusk L, Gotzsche P. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. *CMAJ* 2017;189:E194-E203
8. American Geriatrics Society. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc* 2015; 63:2227-46
9. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride). Drug Approval Package. Major Depressive Disorder. NDA 021427 [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/021427_s000_Cymbalta_BioPharmr_P1.pdf
10. Lunn M, Hughes R, Wiffen P. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. *Cochrane Database of Systematic Reviews* 2014, Issue 1. Art. No. CD007115

Amitriptyline, Nortriptyline

1. Moore R, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2015, Issue 7. Art. No. CD008242
2. CPhA Monograph Tricyclic Antidepressants. Canadian Pharmacists Association, 2018. [Internet]. <https://www.e-therapeutics.ca/>
3. Derry S, Wiffen P, Aldington, et al. Nortriptyline for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2015, Issue 1. Art. No. CD011209
4. Health Canada Product Monograph. Elavil (amitriptyline hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
5. Health Canada Product Monograph. Aventyl (nortriptyline hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
6. Hearne L, Moore R, Derry S, et al. Desipramine for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 9. Art. No. CD011003
7. Hearn L, Derry S, Phillips T, et al. Imipramine for neuropathic pain in adults. *Cochrane Database of Systematic Reviews* 2014, Issue 5. Art. No. CD010769
8. Finnerup N, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* 2015; 14:162-73

9. Hicks J, Sangkuhl K, Swen J, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 Update. *Clin Pharmacol Ther* 2016 Dec 20 [Epub ahead of print].
10. Dean L. Amitriptyline therapy and CYP2D6 and CYP2C19 genotype. *Medical Genetics Summaries* [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK425165/>
11. Gilron I, Bailey J, Dongsheng T, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. *Lancet* 2009;374:1252-61
12. American Geriatrics Society. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc* 2015; 63:2227-46
13. McQuay H, Tramer M, Nye B, et al. A systematic review of antidepressants in neuropathic pain. *Pain* 1996;68:217-27
14. Gray S, Anderson M, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia. A prospective cohort study. *JAMA Int Med* 2015;175:401-407
15. Richardson K, Fox C, Maidment I, et al. Anticholinergic drugs and risk of dementia: case-control study. *BMJ* 2018;360:k1315
16. Page R, O'Bryant C, Cheng D, et al. Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association. *Circulation* 2016;134:1-38
17. CredibleMeds. QTDrugs Lists. [Internet]. <https://www.crediblemeds.org/>.
18. Health Canada. Health Product InfoWatch. [Internet]. https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/medeffect-canada/health-product-infowatch/may-2018/hpiw-ivps_2018-05-eng.pdf
19. Everitt H, Baldwin D, Stuart B, et al. Antidepressants for insomnia in adults. *Cochrane Database of Systematic Reviews* 2018, Issue 5. Art. No. CD010753

Drug Interactions

1. Lexicomp Online. Lexicomp Interactions. [Internet]. <https://online.lexi.com/lco/action/interact>
2. Health Canada Product Monograph. Neurontin (gabapentin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
3. US Food and Drug Administration. Neurontin (gabapentin). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020235s064_020882s047_021129s046lbl.pdf
4. Gomes T, Juurlink D, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. *PLoS Med* 2017;14:e1002396
5. Health Canada Product Monograph. Lyrica (pregabalin). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
6. US Food and Drug Administration. Lyrica (pregabalin). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021446s026,022488s005lbl.pdf
7. Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. *Ann Intern Med* 2018 Aug 21 [Epub ahead of print].
8. Health Canada Product Monograph. Cymbalta (duloxetine delayed release capsules). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
9. US Food and Drug Administration. Cymbalta (duloxetine hydrochloride delayed release capsules). Prescribing Information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022516lbl.pdf
10. Indiana University. Department of Medicine Clinical Pharmacology. Drug Interactions. [Internet]. <http://medicine.iupui.edu/clinpharm/ddis/>
11. Buckley N, Dawson A, Ibister G. Serotonin syndrome. *BMJ* 2014;348:g1626
12. US Food and Drug Administration. Duloxetine (Cymbalta). Bleeding; NME Follow-up. 2007 September 18. [Internet]. <https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103480.pdf>
13. Health Canada Product Monograph. Elavil (amitriptyline hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>

14. Health Canada Product Monograph. Aventyl (nortriptyline hydrochloride). [Internet]. <http://webprod5.hc-sc.gc.ca/dpd-bdpp/>
15. CredibleMeds. QTDrugs Lists. [Internet]. <https://www.crediblemeds.org/>.
16. Health Canada. Health Product InfoWatch. [Internet]. https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-health-products/medeffect-canada/health-product-infowatch/may-2018/hpiw-ivps_2018-05-eng.pdf

Evidence to Practice

1. Krashin D, Sullivan D, Ballantyne J. What are we treating with chronic opioid therapy? *Curr Rheumatol Rep* 2013;15:311
2. Moore A, Derry S, Eccleston C, et al. Expect analgesic failure: pursue analgesic success. *BMJ* 2013;356:f2690